Androgen deprivation therapy (ADT) is a well-established treatment for locally advanced, biochemically recurrent and metastatic prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
However, it is associated with significant side effects including hot flashes, loss of libido and erectile function, muscular atrophy, metabolic abnormalities, and osteoporosis. In attempt to mitigate the side effects of ADT while retaining the oncological benefits, an approach of intermittent ADT (IAD) has been investigated. IAD involves alternating periods of treatment with intervals off treatment to allow hormone recovery. PSA thresholds are triggers for withdrawing and reinitiating therapy. Potential advantages of IAD include improved quality of life with fewer side effects and reduced cost. Delays in the development of hormone resistance have not been demonstrated clinically. The appropriate use of IAD requires patient selection and close monitoring of quality of life and disease status. This review presents the most recent evidence on the role of IAD in the management of prostate cancer.
Jaswal J, Crook J. Are you the author?
Department of Radiation Oncology, British Columbia Cancer Agency, Cancer Centre for the Southern Interior, 399 Royal Avenue, Kelowna, British Columbia, Canada.
Reference: Curr Urol Rep. 2015 Mar;16(3):481.